Cresco Labs: Analyst Q4 2020 Consensus Expectations

Cresco Labs (CSE: CL) announced that they will be reporting their fourth quarter and year-end financials pre-market on March 25th. Analysts have a consensus C$22.22 12-month price target on the company, via a total of 16 analysts, with four analysts having a strong buy rating and the other 11 have buy ratings and one analyst has a hold rating. The street high comes from Stifel-GMP with a C$36 price target, and the lowest target comes from Roth Capital with a C$17.50 price target.

Sixteen analysts have revenue estimates for the fourth quarter. The mean between all 16 is U$161.38 million; this number has been revised downwards from U$162.50 million at the start of the year. Needham & Co currently has the highest revenue estimate with U$167.8 million, while the lowest comes from Piper Sandler with a U$156.1 million estimate.

For the full year, the average revenue estimate between 16 analysts is currently U$475.52 million. This number has been revised downwards from U$475.52 million at the start of the year. The street high comes from Needham & Co with a U$481.70 full-year revenue estimate, while the lowest comes from Piper Sandler with a U$470 million estimate.

Onto EBITDA estimates, there are currently 14 analysts who have fourth-quarter EBITDA estimates. The mean is currently U$48.06 million, with this number roughly the same since the start of the year. Street high goes to Needham & Co with a U$52,14 million EBITDA estimate and the lowest being ATB Capital with a U$42.20 million estimate.

For the full year, the current EBITDA mean across 12 analysts is U$114.13 million. This number is roughly the same since the start of the year. Needham & Co currently has the highest full-year estimate at U$118.21 million and the lowest being Benchmark with a U$158 million estimate.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

First Majestic Q1 Earnings: A Bang Up Quarter

Copper’s Structural Shortage May Be Here to Stay | Colin Joudrie – Selkirk Copper

Why Barrick’s “Strong” Quarter Wasn’t So Strong | Q1 2026 Earnings

Recommended

Altamira Gold Extends Maria Bonita Porphyry System Westward With 70.6 Metres At 0.51 g/t Hit

Antimony Resources Reports 13.9% Antimony in Latest Drill Core at Bald Hill

Related News

Cannabis Earnings: Cantor Fitzgerald Adjusts Ratings Ahead Of Earnings

Last week, Pablo Zuanic from Cantor Fitzgerald released his second-quarter estimates and updated his 12-month...

Wednesday, August 11, 2021, 09:56:00 AM

Haywood Reiterates $12 Price Target On Well Health

On January 20th, Well Health (TSX: WELL) provided a business update which included fourth quarter...

Monday, January 24, 2022, 04:22:00 PM

Kinross: Canaccord Leaves Price Target Unchanged Following Peak Gold Acquisition

Yesterday, Kinross Gold Corp (TSX: L) (NYSE: KGC) announced that they had entered into agreements...

Thursday, October 1, 2020, 03:01:00 PM

Uranium Royalty: Canaccord Gives Price Target A Lift After Physical Purchases

On September 15th, Uranium Royalty Corp. (TSXV: URC) announced that they purchased an additional 300,000...

Monday, September 20, 2021, 11:36:00 AM

Aurora Cannabis: Consensus Price Target Tumbles Following Q3 Results

Aurora Cannabis (TSX: ACB) (NYSE: ACB) reported earnings for their fiscal third-quarter earnings on May...

Sunday, May 16, 2021, 10:16:00 AM